Slide Presentations: Tuesday, October 25, 2011 |

Pooled Safety of Roflumilast and Focus on Gastrointestinal Events in Eight Placebo-Controlled Studies in Patients With Chronic Obstructive Pulmonary Disease FREE TO VIEW

Mark Dransfield, MD; Gary Ferguson, MD; Udo-Michael Goehring, MD; Hans Mosberg, MD; Manja Brose, MS; Dirk Bredenbroeker, MD; Hassan Lakkis, PhD; Paul Rowe, MD
Chest. 2011;140(4_MeetingAbstracts):976A. doi:10.1378/chest.1115658
Text Size: A A A
Published online


PURPOSE: The phosphodiesterase-4 inhibitor roflumilast was approved by the FDA to reduce the risk of exacerbations in COPD patients with severe disease, chronic bronchitis and a history of acute exacerbations. This safety evaluation of 8 studies enrolled patients that were representative of the anticipated approval population receiving 500µg of roflumilast. By focusing on these 8 studies, this analysis may have improved relevance and sensitivity for adverse event (AE) frequencies, compared to previously reported broader multiple-dose safety pool results. Given previously demonstrated associations between phosphodiesterase-4 inhibitors and gastrointestinal (GI) AEs, we examined the frequency of common AEs and GI-AEs using pooled data from the 8 studies, reported in detail for the first time here.

METHODS: Data were pooled from eight 24-52-week, placebo-controlled, phase 2/3 clinical trials of roflumilast 500µg in moderate-to-very severe COPD patients. Frequencies of the most common AEs (≥2% for roflumilast and >placebo) and GI-AEs ≥1% and >placebo are reported.

RESULTS: In this analysis, n=4438 for roflumilast and n=4192 for placebo. The most frequently reported AEs (≥2% higher for roflumilast vs placebo) were diarrhea (9.5% vs 2.7%), weight decreased (7.5%, vs 2.1%), nausea (4.7% vs 1.4%), and headache (4.4% vs 2.1%). Back pain, influenza, insomnia, dizziness, and decreased appetite were reported by ≥2% of patients treated with roflumilast but were <2% greater than placebo. Apart from diarrhea and nausea, other GI-AEs ≥1% with roflumilast and >placebo were abdominal pain (1.9% vs 0.9%), upper abdominal pain (1.3% vs 0.6%), dyspepsia (1.2% vs 1.0%), gastritis (1.1% vs 0.4%) and vomiting (1.3% vs 0.7%). Other than weight decreased and decreased appetite (2.1% vs 0.4%), no other metabolism or investigation AEs were ≥1.0% with roflumilast and >placebo.

CONCLUSIONS: In this pool of 8 COPD trials, roflumilast treatment resulted in no AEs ≥10% and most ≤5% greater than placebo. Roflumilast was associated with more frequent GI-AEs than placebo, although most were ≤2%.

CLINICAL IMPLICATIONS: AE rates observed in this 8-study population, containing patients representative of those approved for roflumilast, were as expected.

DISCLOSURE: Mark Dransfield: Grant monies (from industry related sources): NIH (NHLBI), Other: GSK, Boehringer Ingelheim, Asthmatx, Consultant fee, speaker bureau, advisory committee, etc.: GSK, Boehringer Ingelheim, Vertex, Forest Laboratories, Inc.

Gary Ferguson: Consultant fee, speaker bureau, advisory committee, etc.: Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Pfizer and Pearl, Grant monies (from industry related sources): Boehringer-Ingelheim, Forest, GlaxoSmithKline, Novartis and Pearl

Udo-Michael Goehring: Employee: Nycomed GmbH

Hans Mosberg: Employee: Nycomed GmbH

Manja Brose: Employee: Nycomed GmbH

Dirk Bredenbroeker: Employee: Nycomed GmbH

Hassan Lakkis: Employee: Forest Research Institute

Paul Rowe: Employee: Forest Research Institute

No Product/Research Disclosure Information

11:30 AM - 12:45 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543